We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Conatus Pharmaceuticals's financial performance into perspective.
Jul 26, 2017
Jul 6, 2017
Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of $7 Million Payment
Events & Presentations
Aug 2, 2017 at 4:30 PM ET